Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

Dick C Chan, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott, P Hugh R Barrett, Dick C Chan, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott, P Hugh R Barrett

Abstract

Objective: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) and statins are known to lower plasma LDL (low-density lipoprotein)-cholesterol concentrations. However, the comparative effects of these treatments on the postprandial metabolism of TRLs (triglyceride-rich lipoproteins) remain to be investigated.

Approach and results: We performed a 2-by-2 factorial trial of the effects of 8 weeks of subcutaneous evolocumab (420 mg every 2 weeks) and atorvastatin (80 mg daily) on postprandial TRL metabolism in 80 healthy, normolipidemic men after ingestion of an oral fat load. We evaluated plasma total and incremental area under the curves for triglycerides, apo (apolipoprotein)B-48, and VLDL (very-LDL)-apoB-100. We also examined the kinetics of apoB-48 using intravenous D3-leucine administration, mass spectrometry, and multicompartmental modeling. Atorvastatin and evolocumab independently lowered postprandial VLDL-apoB-100 total area under the curves (P<0.001). Atorvastatin, but not evolocumab, reduced fasting plasma apoB-48, apoC-III, and angiopoietin-like 3 concentrations (P<0.01), as well as postprandial triglyceride and apoB-48 total area under the curves (P<0.001) and the incremental area under the curves for plasma triglycerides, apoB-48, and VLDL-apoB-100 (P<0.01). Atorvastatin also independently increased TRL apoB-48 fractional catabolic rate (P<0.001) and reduced the number of apoB-48-containing particles secreted in response to the fat load (P<0.01). In contrast, evolocumab did not significantly alter the kinetics of apoB-48.

Conclusions: In healthy, normolipidemic men, atorvastatin decreased fasting and postprandial apoB-48 concentration by accelerating the catabolism of apoB-48 particles and reducing apoB-48 particle secretion in response to a fat load. Inhibition of PCSK9 with evolocumab had no significant effect on apoB-48 metabolism.

Keywords: fasting; leucine; lipoproteins; mass spectrometry; triglycerides.

© 2018 American Heart Association, Inc.

Figures

Figure 1.
Figure 1.
Plasma triglyceride (A), VLDL-apoB-100 (B), and apoB-48 (C) responses to the fat load in the placebo, atorvastatin, evolocumab, and atorvastatin plus evolocumab groups. Values are expressed as mean±SEM. Apo indicates apolipoprotein; and VLDL, very-low-density lipoprotein.
Figure 2.
Figure 2.
Ratio of geometric means (post/preintervention) for main effects of atorvastatin and evolocumab on the total and incremental area under the curves (AUCs) for plasma triglycerides (A and B), VLDL-apoB-100 (C and D), and apoB-48 (E and F). Apo indicates apolipoprotein; and VLDL, very-low-density lipoprotein.
Figure 3.
Figure 3.
Tracer/tracee ratio of leucine in apoB-48 at preintervention and postintervention in a representative subject from the placebo (A), atorvastatin (B), evolocumab (C), and atorvastatin plus evolocumab (D) groups. Apo indicates apolipoprotein.
Figure 4.
Figure 4.
Ratio of geometric means (post/preintervention) for main effects of atorvastatin and evolocumab on the apoB-48 pool size (A), apoB-48 FCR (B), basal apoB-48 PR (C), and apoB-48 particle secreted on the top of basal apoB-48 secretion (D). Apo indicates apolipoprotein; CI, confidence interval; FCR, fractional catabolic rate; and PR, production rate.

References

    1. Havel RJ. Triglyceride-rich lipoproteins and plasma lipid transport. Arterioscler Thromb Vasc Biol. 2019;30:9–19. doi: 10.1161/ATVBAHA.108.178756.
    1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473–485.
    1. Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:2525–2540. doi: 10.1016/j.jacc.2014.09.042.
    1. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–563. doi: 10.1161/CIRCRESAHA.115.306249.
    1. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287–1295. doi: 10.1172/JCI112713.
    1. Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126:2855–2866. doi: 10.1172/JCI86610.
    1. Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52:187–193. doi: 10.1007/s12020-015-0838-9.
    1. Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, Furukawa H. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742–33748. doi: 10.1074/jbc.M203215200.
    1. Sundaram M, Zhong SM, Khalil MB, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang YW, Yao Z. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150–161. doi: 10.1194/M900346-JLR200.
    1. Grundy SM. Statins: definitive translational research. Mol Med. 2014;20(suppl 1):S20–S23. doi: 10.2119/molmed.2014.00194.
    1. Kim S, Kim CH, Vaziri ND. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol Endocrinol Metab. 2005;288:E813–E817. doi: 10.1152/ajpendo.00266.2004.
    1. Imagawa M, Takahashi S, Zenimaru Y, Kimura T, Suzuki J, Miyamori I, Iwasaki T, Hattori H, Yamamoto TT, Nakano T, Nakajima K. Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: effect of a high-dose statin on VLDL receptor expression. Clin Chim Acta. 2012;413:441–447. doi: 10.1016/j.cca.2011.10.033.
    1. Chan DC, Watts GF, Barrett PH, Martins IJ, James AP, Mamo JC, Mori TA, Redgrave TG. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res. 2002;43:706–712.
    1. Ng TW, Watts GF, Stuckey BG, Ching HL, Chan DC, Uchida Y, Sakai N, Yamashita S, Martins IJ, Redgrave TG, Barrett PH. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus? Clin Endocrinol (Oxf) 2005;63:650–656. doi: 10.1111/j.1365-2265.2005.02396.x.
    1. Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 2000;85:4224–4230. doi: 10.1210/jcem.85.11.6978.
    1. Parhofer KG, Laubach E, Barrett PH. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res. 2003;44:1192–1198. doi: 10.1194/jlr.M300011-JLR200.
    1. Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism? Metabolism. 2000;49:1049–1054. doi: 10.1053/meta.2000.7744.
    1. Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, Jones PH, Schaefer EJ. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009;205:197–201. doi: 10.1016/j.atherosclerosis.2008.11.001.
    1. Burnett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler Thromb Vasc Biol. 1998;18:1906–1914.
    1. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–1036. doi: 10.1161/CIRCRESAHA.114.301621.
    1. Druce I, Abujrad H, Ooi TC. PCSK9 and triglyceride-rich lipoprotein metabolism. J Biomed Res. 2015;29:429–436. doi: 10.7555/JBR.29.20150052.
    1. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(suppl):S172–S177. doi: 10.1194/jlr.R800091-JLR200.
    1. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363–2372. doi: 10.1074/jbc.M708098200.
    1. Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 2013;8:e64145. doi: 10.1371/journal.pone.0064145.
    1. Le May C, Kourimate S, Langhi C, Chétiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684–690. doi: 10.1161/ATVBAHA.108.181586.
    1. Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF. The effect of PCSK9 loss-of-function variants on the postprandial lipid and ApoB-lipoprotein response. J Clin Endocrinol Metab. 2017;102:3452–3460. doi: 10.1210/jc.2017-00684.
    1. Chan DC, Wong AT, Pang J, Barrett PH, Watts GF. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. Clin Sci (Lond) 2015;128:379–385. doi: 10.1042/CS20140559.
    1. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 Extension Study. JAMA Cardiol. 2017;2:598–607. doi: 10.1001/jamacardio.2017.0747.
    1. Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation. 2017;135:338–351. doi: 10.1161/CIRCULATIONAHA.116.025080.
    1. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499. doi: 10.1056/NEJMoa1501031.
    1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664.
    1. Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352–362. doi: 10.1161/CIRCULATIONAHA.116.025253.
    1. Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest. 1999;29:204–209.
    1. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM, Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12:1336–1345.
    1. Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:384–391. doi: 10.1111/dom.12622.
    1. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF. Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab. 2014;99:E1427–E1435. doi: 10.1210/jc.2013-4037.
    1. Dwyer KP, Barrett PH, Chan D, Foo JI, Watts GF, Croft KD. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J Lipid Res. 2002;43:344–349.
    1. Le NA, Coates PM, Gallagher PR, Cortner JA. Kinetics of retinyl esters during postprandial lipemia in man: a compartmental model. Metabolism. 1997;46:584–594.
    1. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, Dolnikowski GG, Horvath K, Asztalos BF, Zago V, Schaefer EJ. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res. 2007;48:1746–1753. doi: 10.1194/jlr.M700067-JLR200.
    1. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res. 2009;50:1463–1471. doi: 10.1194/jlr.P800061-JLR200.
    1. Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57:246–254. doi: 10.1016/j.metabol.2007.09.008.
    1. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997;38:2173–2192.
    1. Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PH. Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr. 2010;91:900–906. doi: 10.3945/ajcn.2009.28422.
    1. Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011;269:333–339. doi: 10.1111/j.1365-2796.2010.02305.x.
    1. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37:439–447.
    1. Pal S, Allister E, Thomson A, Mamo JC. Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis. 2002;161:55–63.
    1. Pau E, He Y, Lougheed M, Steinbrecher UP. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells. Biochem Cell Biol. 1995;73:81–90.
    1. Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia. Eur J Pharmacol. 2002;444:107–113. doi: 10.1016/S0014-2999(02)01547-9.
    1. Phillips C, Mullan K, Owens D, Tomkin GH. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis. 2006;187:57–64. doi: 10.1016/j.atherosclerosis.2005.08.020.
    1. Xiao C, Dash S, Morgantini C, Adeli K, Lewis GF. Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism. Diabetes. 2015;64:2310–2318. doi: 10.2337/db14-1706.
    1. Taldone T, Zito SW, Talele TT. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008;18:479–484. doi: 10.1016/j.bmcl.2007.11.107.
    1. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014;130:431–441. doi: 10.1161/CIRCULATIONAHA.113.006720.
    1. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995–2006. doi: 10.1016/S0140-6736(12)61771-1.
    1. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531–2540. doi: 10.1016/j.jacc.2014.03.018.
    1. Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol. 2016;27:233–241. doi: 10.1097/MOL.0000000000000297.
    1. Kobayashi J, Miyashita K, Nakajima K, Mabuchi H. Hepatic Lipase: a Comprehensive view of its role on plasma lipid and lipoprotein metabolism. J Atheroscler Thromb. 2015;22:1001–1011. doi: 10.5551/jat.31617.
    1. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis. 2004;175:325–331. doi: 10.1016/j.atherosclerosis.2004.04.003.
    1. Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H DALI Study Group. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care. 2003;26:427–432.
    1. Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of evolocumab on lipoprotein particles. Am J Cardiol. 2018;121:308–314. doi: 10.1016/j.amjcard.2017.10.028.
    1. Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES Study. Circ Res. 2015;117:731–741. doi: 10.1161/CIRCRESAHA.115.307071.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe